中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.033 seconds)

    Solid dispersions containing an apoptosis-inducing agent
    1.
    发明授权
    Solid dispersions containing an apoptosis-inducing agent 有权

    公开(公告)号：US10213433B2

    公开(公告)日：2019-02-26

    申请号：US14537392

    申请日：2014-11-10

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/397 ,  A61K31/5377 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437 ,  A61K31/496

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    4.
    发明申请
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT 有权

    公开(公告)号：US20250161318A1

    公开(公告)日：2025-05-22

    申请号：US18809439

    申请日：2024-08-20

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/5377 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437 ,  A61K31/496

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    7.
    发明申请
    MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT 审中-公开
    含有药物诱导剂的熔融挤出固体分散体

    公开(公告)号：US20150148331A1

    公开(公告)日：2015-05-28

    申请号：US14340435

    申请日：2014-07-24

    Applicant: AbbVie Inc. ,  AbbVie Deutschland GMBH & Co KG

    Inventor： Esther Birtalan ,  Peter Hoelig ,  David J. Lindley ,  Yeshwant D. Sanzgiri ,  Ping Tong

    IPC: A61K31/496 ,  A61K31/541 ,  A61K9/00 ,  A61K47/32 ,  A61K47/26 ,  A61K31/5377 ,  A61K47/02

    CPC classification number: A61K31/496 ,  A61K9/0053 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2095 ,  A61K31/5377 ,  A61K31/541 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

    Abstract translation: 促凋亡固体分散体以基本上非结晶形式包含分散在固体基质中的如本文定义的式I的Bcl-2家族蛋白质抑制化合物，其包含（a）药学上可接受的水溶性聚合物载体和（ b）药学上可接受的表面活性剂。 制备这种固体分散体的方法包括使升高的温度使式I化合物，水溶性聚合物载体和表面活性剂提供可挤出的半固体混合物; 挤出半固体混合物; 并冷却所得挤出物以提供包含聚合物载体和表面活性剂的固体基质，并使化合物以基本上非结晶形式分散在其中。 固体分散体适合于有需要的受试者口服给药以治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症或免疫或自身免疫性疾病）过表达为特征的疾病。

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    8.
    发明申请
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20190275051A1

    公开(公告)日：2019-09-12

    申请号：US16239199

    申请日：2019-01-03

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/5377 ,  A61K9/48 ,  A61K31/496 ,  A61K31/437 ,  A61K9/14 ,  A61K9/16

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Patent Agency Ranking